HealthCare Institute of New Jersey responds to CDC changes in vaccine recommendations

Chrissy Buteas President and Chief Executive Officer - HealthCare Institute of New Jersey
Chrissy Buteas President and Chief Executive Officer - HealthCare Institute of New Jersey
0Comments

The HealthCare Institute of New Jersey (HINJ) has responded to the Centers for Disease Control and Prevention’s (CDC) recent decision to reduce the number of recommended childhood vaccines. The CDC now recommends immunization against 11 diseases, down from the previous 17. Vaccines for influenza, COVID-19, rotavirus, and hepatitis A and B have been moved to a “shared clinical decision-making” category. This means these vaccines are no longer universally recommended for all children but remain available for high-risk groups or at parental request.

Chrissy Buteas, president and CEO of HINJ, issued a statement following the CDC’s announcement: “Vaccines remain a ‘critical pillar’ of global stability and public health.”



Related

Bob Considine Chief Communications Officer

Children’s Specialized Hospital and workforce summit featured on Minding Your Business

Children’s Specialized Hospital President Dr. Matthew McDonald discussed pediatric care advancements on “Minding Your Business.” The episode also covered insights from NJBIA’s Workforce Summit featuring Lt. Gov. Dale Caldwell.

Michele Siekerka President & CEO

Data shows New Jersey ranks among top five in state and local tax collections

New data from the Tax Foundation places New Jersey among America’s top five states for highest per capita state and local tax collections for fiscal year 2023. Policy analysts point out factors such as progressive income taxes and unique revenue sources behind these rankings.

Chrissy Buteas President and Chief Executive Officer - HealthCare Institute of New Jersey

HealthCare Institute of New Jersey comments on passage of Patient and Provider Protection Act

Chrissy Buteas of HINJ commented on legislative efforts aimed at lowering patient costs after A-1502 passed committee review. The statement highlighted concerns about pharmacy benefit managers’ roles in drug pricing. HINJ also emphasized its broader mission supporting healthcare innovation.

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from New Jersey Review.